Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney
- PMID: 17324946
- DOI: 10.1093/ndt/gfl780
Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney
Abstract
Background: Angiotensin II blockade and spironolactone effectively reduces proteinuria in humans. To clarify the mechanisms of the beneficial effect of blockade of both aldosterone and angiotensin II, we associated the aldosterone antagonist eplerenone to an angiotensin-converting enzyme inhibitor (ACEI) and examined the effect on renal transforming growth factor (TGF)-beta expression and oxidative stress by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in the Dahl salt-sensitive rat with heart failure (DSHF).
Methods: Dahl salt-resistant control rats and DSHF rats were fed with 8% NaCl diet and at 11 weeks the DSHF rats were treated with vehicle, eplerenone (Epl), trandolapril or a combination of both drugs for 7 weeks.
Results: DSHF rats showed increased NADPH oxidase and decreased superoxide dismutase (SOD) resulting in increased oxidative stress. ACEI and Epl reduced NADPH oxidase showing an additive effect in their combination; ACEI increased manganese SOD (MnSOD) and Epl increased MnSOD, copper-zinc SOD and catalase, resulting in the lowest levels of oxidative stress with the combination therapy. Glomerulosclerosis and proteinuria were increased in the DSHF rats, and Epl suppressed them more effectively than ACEI to levels not different from the combination of both, showing a positive correlation with NADPH oxidase expression and TGF-beta. Renal TGF-beta was specifically suppressed with Epl
Conclusion: The association of Epl to ACEI is beneficial due to further reduction of NADPH oxidase and specific inhibition of TGF-beta resulting in improvement of renal damage.
Similar articles
-
Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.Clin Exp Hypertens. 2006 Feb;28(2):121-32. doi: 10.1080/10641960500468276. Clin Exp Hypertens. 2006. PMID: 16546838
-
Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.J Cardiovasc Pharmacol. 2012 Aug;60(2):140-9. doi: 10.1097/FJC.0b013e318258f8ce. J Cardiovasc Pharmacol. 2012. PMID: 22549451
-
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.Am J Hypertens. 2007 Oct;20(10):1119-24. doi: 10.1016/j.amjhyper.2007.05.008. Am J Hypertens. 2007. PMID: 17903697
-
Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.Hypertens Res. 2009 May;32(5):321-4. doi: 10.1038/hr.2009.29. Epub 2009 Mar 20. Hypertens Res. 2009. PMID: 19300447 Review.
-
Mineralocorticoid receptor antagonist for renal protection.Ren Fail. 2012;34(6):810-7. doi: 10.3109/0886022X.2012.672156. Epub 2012 Apr 2. Ren Fail. 2012. PMID: 22463731 Review.
Cited by
-
Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis.Nephron Extra. 2012 Jan;2(1):17-26. doi: 10.1159/000334961. Epub 2012 Jan 31. Nephron Extra. 2012. PMID: 22479265 Free PMC article.
-
Aldosterone: effects on the kidney and cardiovascular system.Nat Rev Nephrol. 2010 May;6(5):261-73. doi: 10.1038/nrneph.2010.30. Epub 2010 Mar 16. Nat Rev Nephrol. 2010. PMID: 20234356 Review.
-
Aldosterone and TGF-β₁ synergistically increase PAI-1 expression in hepatic stellate cells of rats.Int J Clin Exp Pathol. 2015 Sep 1;8(9):9845-53. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26617694 Free PMC article.
-
Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate.Indian Heart J. 2017 Mar-Apr;69(2):255-265. doi: 10.1016/j.ihj.2017.01.005. Epub 2017 Jan 22. Indian Heart J. 2017. PMID: 28460776 Free PMC article. Review.
-
Transcription factor avian erythroblastosis virus E26 oncogen homolog-1 is a novel mediator of renal injury in salt-sensitive hypertension.Hypertension. 2015 Apr;65(4):813-20. doi: 10.1161/HYPERTENSIONAHA.114.04533. Epub 2015 Jan 26. Hypertension. 2015. PMID: 25624342 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical